Fibrodysplasia Ossificans Progressiva Pipeline Report, 2024 Updates : In-Depth Analysis Into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects and Companies

Fibrodysplasia Ossificans Progressiva

The Fibrodysplasia Ossificans Progressiva Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Fibrodysplasia Ossificans Progressiva Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva Market.

Some of the key takeaways from the Fibrodysplasia Ossificans Progressiva Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Fibrodysplasia Ossificans Progressiva treatment therapies with a considerable amount of success over the years. 
  • Fibrodysplasia Ossificans Progressiva companies working in the treatment market are Daiichi Sankyo Co., Ltd, AstraZeneca, Ipsen, Incyte Corporation, Nobelpharma, Regeneron Pharmaceuticals, and others, are developing therapies for the Fibrodysplasia Ossificans Progressiva treatment 
  • Emerging Fibrodysplasia Ossificans Progressiva therapies in the different phases of clinical trials are- DS 6016, Saracatinib, Fidrisertib, INCB-00928, NPC-12T, Garetosmab, and others are expected to have a significant impact on the Fibrodysplasia Ossificans Progressiva market in the coming years.   
  • In June 2023,  Ipsen (Euronext: IPN; ADR: IPSEY) announced that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) approved investigational palovarotene as an effective treatment for people with the extremely rare bone disease fibrodysplasia ossificans progressiva (FOP), with a favourable risk-benefit profile. Palovarotene’s New Drug Application (NDA) is being reviewed by the FDA, and a decision is expected on August 16, 2023. Palovarotene will be the first FOP medication offered in the US if approved
  • In November 2022, A trial titled “Phase 3 Randomised, PlaceboControlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva” was started by Regeneron Pharmaceuticals.

Fibrodysplasia Ossificans Progressiva Overview

Heterotopic ossification, a very rare genetic connective tissue illness, causes abnormal bone growth in parts of the body other than those where bone is ordinarily found, such as the ligaments, tendons, and skeletal muscles.

Source: AB News Wire